Leishmaniasis Vaccines: Applications of RNA Technology and Targeted Clinical Trial Designs
Open Access
Abstract
Leishmania parasites cause a variety of discrete clinical diseases that present in regions where their specific sand fly vectors sustain transmission. Clinical and laboratory research indicate the potential of immunization to prevent leishmaniasis and a wide array of vaccine candidates have been proposed. Unfortunately, multiple factors have precluded advancement of more than a few Leishmania targeting vaccines to clinical trial. The recent maturation of RNA vaccines into licensed products in the context of COVID-19 indicates the likelihood of broader use of the technology. Herein, we discuss the potential benefits provided by RNA technology as an approach to address the bottlenecks encountered for Leishmania vaccines. Further, we outline a variety of strategies that could be used to more efficiently evaluate Leishmania vaccine efficacy, including controlled human infection models and initial use in a therapeutic setting, that could prioritize candidates before evaluation in larger, longer and more complicated field trials.Keywords
Funding Information
- National Institute of Allergy and Infectious Diseases of the National Institutes of Health (R01AI025038, #631, #39129, G2018–111, #62966, WT 085879, 108518, MR/P022030)
- Bill and Melinda Gates Foundation (R01AI025038, #631, #39129, G2018–111, #62966, WT 085879, 108518, MR/P022030)
- Global Health Innovative Technology Fund (R01AI025038, #631, #39129, G2018–111, #62966, WT 085879, 108518, MR/P022030)
- CRDF Global (R01AI025038, #631, #39129, G2018–111, #62966, WT 085879, 108518, MR/P022030)
- Wellcome Trust (R01AI025038, #631, #39129, G2018–111, #62966, WT 085879, 108518, MR/P022030)
- UK Medical Research Council (R01AI025038, #631, #39129, G2018–111, #62966, WT 085879, 108518, MR/P022030)
This publication has 89 references indexed in Scilit:
- T Helper1/T Helper2 Cells and Resistance/Susceptibility to Leishmania Infection: Is This Paradigm Still Relevant?Frontiers in Immunology, 2012
- Optimized subunit vaccine protects against experimental leishmaniasisVaccine, 2009
- Developments in the treatment of visceral leishmaniasisExpert Opinion on Emerging Drugs, 2009
- Photodynamic vaccination of hamsters with inducible suicidal mutants of Leishmania amazonensis elicits immunity against visceral leishmaniasisEuropean Journal of Immunology, 2009
- Nonviral Vectors for Gene DeliveryChemical Reviews, 2008
- Immunization with H1, HASPB1 and MML Leishmania proteins in a vaccine trial against experimental canine leishmaniasisVaccine, 2007
- Peptide-guided gene deliveryThe AAPS Journal, 2007
- Failure of a multi-subunit recombinant leishmanial vaccine (MML) to protect dogs from Leishmania infantum infection and to prevent disease progression in infected animalsVaccine, 2005
- Design and development of polymers for gene deliveryNature Reviews Drug Discovery, 2005
- Recombinant interleukin 12 cures mice infected with Leishmania major.Journal of Experimental Medicine, 1993